KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Free Cash Flow (2016 - 2025)

Rigel Pharmaceuticals has reported Free Cash Flow over the past 16 years, most recently at $22.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $22.0 million for Q4 2025, up 51.91% from a year ago — trailing twelve months through Dec 2025 was $75.7 million (up 140.63% YoY), and the annual figure for FY2025 was $75.7 million, up 140.67%.
  • Free Cash Flow for Q4 2025 was $22.0 million at Rigel Pharmaceuticals, down from $24.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for RIGL hit a ceiling of $54.8 million in Q2 2021 and a floor of -$25.9 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$2.7 million (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 441.24% in 2021 and later surged 10011.59% in 2025.
  • Rigel Pharmaceuticals' Free Cash Flow stood at -$19.1 million in 2021, then decreased by 15.3% to -$22.0 million in 2022, then skyrocketed by 71.61% to -$6.2 million in 2023, then skyrocketed by 332.0% to $14.5 million in 2024, then soared by 51.91% to $22.0 million in 2025.
  • The last three reported values for Free Cash Flow were $22.0 million (Q4 2025), $24.0 million (Q3 2025), and $30.5 million (Q2 2025) per Business Quant data.